Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dienogest + ethinyl estradiol
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dienogest + ethinyl estradiol is a **fixed-dose combined oral contraceptive** containing the antiandrogenic progestin dienogest and the synthetic estrogen ethinyl estradiol. Common products contain dienogest 2 mg plus ethinyl estradiol 0.03 mg in oral tablets. The combination suppresses hypothalamic-pituitary-ovarian signaling and ovulation, thickens cervical mucus, and produces endometrial changes that reduce the likelihood of fertilization and implantation. It is marketed for contraception and, in some jurisdictions, for moderate acne vulgaris in women who choose oral contraception. Bayer developed and marketed the reference product Valette; generic and regional products include Oralia from IFA Celtics.
- Brand names
- BonadeaDiecyclenDienilDienilleDienobelDienoretteDienovelEstroplusFoxinette NeoJeanineKappanogestLisaMaximMistraMotionMotion RatiopharmOmissonOmisson DailyOraliaPaolettaRaenerSerisima ContinuSienimaValetteVerezanaViola
- Other names
- dienogest + ethinyl estradioldienogest + ethinylestradiolethinyl estradiol + dienogestethinylestradiol + dienogest
02
Targets
PR (Progesterone receptor)ESR1 (ERα)GPER1 (G protein-coupled estrogen receptor 1)ESR2 (ERβ)AR (Adrenergic receptors)
Beyond the preview
Go deeper on dienogest + ethinyl estradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dienogest + ethinyl estradiol.